γ-radiation-induced chromosomal mutagen sensitivity is associated with breast cancer risk in African-American women: Caffeine modulates the outcome of mutagen sensitivity assay

Cancer Epidemiology Biomarkers and Prevention

Volumn 15, Issue 3, 2006, Pages 437-442

  Natarajan, Thanemozhi G ^a   Ganesan, Natarajan ^a   Carter Nolan, Pamela ^b   Tucker, Cynthia A ^b   Shields, Peter G ^a   Adams Campbell, Lucile L ^b  

^a GEORGETOWN UNIVERSITY   (United States)

^b HOWARD UNIVERSITY CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; MUTAGENIC AGENT;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CANCER SCREENING; CELL CULTURE; CELL CYCLE G2 PHASE; CHROMOSOME ABERRATION; CHROMOSOME MUTATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CULTURAL FACTOR; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DNA REPAIR; FEMALE; GAMMA RADIATION; GENETIC PREDISPOSITION; HUMAN; LYMPHOCYTE; MAJOR CLINICAL STUDY; METAPHASE; MITOSIS INHIBITION; MUTAGEN SENSITIVITY ASSAY; MUTAGEN TESTING; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT;

ADULT; AFRICAN AMERICANS; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CAFFEINE; CASE-CONTROL STUDIES; CELLS, CULTURED; CHROMOSOME ABERRATIONS; DNA DAMAGE; FEMALE; GAMMA RAYS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; LYMPHOCYTES; MIDDLE AGED; MUTAGENICITY TESTS; PROBABILITY; REFERENCE VALUES; RISK ASSESSMENT; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 33645510212     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-05-0353     Document Type: Article

References (57)

1. Peto J, Collins N, Barfoot R, et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer [see comments]. J Natl Cancer Inst 1999;91:943-9.
2. Weber BL, Nathanson KL. Low penetrance genes associated with increased risk for breast cancer. Eur J Cancer 2000;36:1193-9.
3. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11:1513-30.
4. Paz-Elizur T, Brenner DE, Livneh Z. Interrogating DNA repair in cancer risk assessment. Cancer Epidemiol Biomarkers Prev 2005;14:1585-7.
5. Wu X, Gu J, Patt Y, et al. Mutagen sensitivity as a susceptibility marker for human hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 1998;7:567-70.
6. Spitz MR, Hsu TC, Wu X, Fueger JJ, Amos CI, Roth JA. Mutagen sensitivity as a biological marker of lung cancer risk in African Americans. Cancer Epidemiol Biomarkers Prev 1995;4:99-103.
7. Zheng YL, Loffredo CA, Yu Z, et al. Bleomycin-induced chromosome breaks as a risk marker for lung cancer: a case-control study with population and hospital controls. Carcinogenesis 2003;24:269-74.
8. Wei Q, Gu J, Cheng L, et al. Benzo(a)pyrene diol epoxide-induced chromosomal aberrations and risk of lung cancer. Cancer Res 1996;56:3975-9.
9. Wang LE, Sturgis EM, Eicher SA, Spitz MR, Hong WK, Wei Q. Mutagen sensitivity to benzo(a)pyrene diol epoxide and the risk of squamous cell carcinoma of the head and neck. Clin Cancer Res 1998;4:1773-8.
10. Wu X, Gu J, Hong WK, et al. Benzo[a]pyrene diol epoxide and bleomycin sensitivity and susceptibility to cancer of upper aerodigestive tract. J Natl Cancer Inst 1998;90:1393-9.
11. Cloos J, Spitz MR, Schantz SP, et al. Genetic susceptibility to head and neck squamous cell carcinoma. J Natl Cancer Inst 1996;88:530-5.
12. Gajecka M, Rydzanicz M, Jaskula-Sztul R, Wierzbicka M, Szyfter W, Szyfter K. Reduced DNA repair capacity in laryngeal cancer subjects. A comparison of phenotypic and genotypic results. Adv Otorhinolaryngol 2005;62:25-37.
13. Spitz MR, Hoque A, Trizna Z, et al. Mutagen sensitivity as a risk factor for second malignant rumors following malignancies of the upper aerodigestive tract [see comments]. J Natl Cancer Inst 1994;86:1681-4.
14. Szekely G, Remenar E, Kasler M, Gundy S. Mutagen sensitivity of patients with cancer at different sites of the head and neck. Mutagenesis 2005; 20:381-5.
15. Bondy ML, Wang LE, el Zein R, et al. γ-Radiation sensitivity and risk of glioma. J Natl Cancer Inst 2001;93:1553-7.
16. Scott D, Spreadborough AR, Roberts SA. Radiation-induced G2 delay and spontaneous chromosome aberrations in ataxia-telangiectasia homozygotes and heterozygotes. Int J Radiat Biol 1994;66:S157-63.
17. Scott D, Barber JB, Levine EL, Burrill W, Roberts SA. Radiation-induced micronucleus induction in lymphocytes identifies a high frequency of radiosensitive cases among breast cancer patients: a test for predisposition? Br J Cancer 1998;77:614-20.
18. Parshad R, Price FM, Bohr VA, Cowans KH, Zujewski JA, Sanford KK. Deficient DNA repair capacity, a predisposing factor in breast cancer. Br J Cancer 1996;74:1-5.
19. Patel RK, Trivedi AH, Arora DC, Bhatavdekar JM, Patel DD. DNA repair proficiency in breast cancer patients and their first-degree relatives. Int J Cancer 1997;73:20-4.
20. Terzoudi GI, Jung T, Hain J, et al. Increased G2 chromosomal radiosensitivity in cancer patients: the role of cdk1/cyclin-B activity level in the mechanisms involved. Int J Radiat Biol 2000;76:607-15.
21. Baria K, Warren C, Roberts SA, West CM, Scott D. Chromosomal radiosensitivity as a marker of predisposition to common cancers? Br J Cancer 2001;84:892-6.
22. Riches AC, Bryant PE, Steel CM, et al. Chromosomal radiosensitivity in G2-phase lymphocytes identifies breast cancer patients with distinctive rumour characteristics. Br J Cancer 2001;85:1157-61.
23. Xiong P, Bondy ML, Li D, et al. Sensitivity to benzo(a)pyrene diol-epoxide associated with risk of breast cancer in young women and modulation by gluthathione S-transferase polymorphisms: a case-control study. Cancer Res 2001;61:8465-9.
24. Gu J, Bondy ML, Sigurdson A, Spitz MR, Hsu TC, Wu X. Three measures of mutagen sensitivity in a cancer-free population. Cancer Genet Cytogenet 1999;110:65-9.
25. Buchholz TA, Wu X. Radiation-induced chromatid breaks as a predictor of breast cancer risk. Int J Radiat Oncol Biol Phys 2001;49:533-7.
26. Helzlsouer KJ, Selmin O, Huang HY, et al. Association between glutathione S-transferase M1, P1, and T1 genetic polymorphisms and development of breast cancer [see comments]. J Natl Cancer Inst 1998;90:512-8.
27. Scott D, Spreadborough A, Levine E, Roberts SA. Genetic predisposition in breast cancer. Lancet 1994;344:1444.
28. Newman LA. Breast cancer in African-American women. Oncologist 2005; 10:1-14.
29. Porter PL, Lund MJ, Lin MG, et al. Racial differences in the expression of cell cycle-regulatory proteins in breast carcinoma. Cancer 2004;100:2533-42.
30. Ademuyiwa FO, Olopade OI. Racial differences in genetic factors associated with breast cancer. Cancer Metastasis Rev 2003;22:47-53.
31. Puck TT, Johnson R, Rasumussen S. A system for mutation measurement in mammalian cells: application to γ-irradiation. Proc Natl Acad Sci U S A 1997;94:1218-23.
32. Dornfeld KJ, Lawrence TS. A predisposition supposition for glioma. J Natl Cancer Inst 2001;93:1512-3.
33. Ning S, Knox SJ. G2/M-phase arrest and death by apoptosis of HL60 cells irradiated with exponentially decreasing low-dose-rate γradiation. Radiat Res 1999;151:659-69.
34. Tenzer A, Pruschy M. Potentiation of DNA-damage-induced cytotoxicity by G2 checkpoint abrogators. Curr Med Chem Anticancer Agents 2003;3:35-46.
35. Powell SN, DeFrank JS, Connell P, et al. Differential sensitivity of p53(-) and p53(+) cells to caffeine-induced radiosensitization and override of G2 delay. Cancer Res 1995;55:1643-8.
36. Loeb KR, Loeb LA. Significance of multiple mutations in cancer. Carcinogenesis 2000;21:379-85.
37. McGuinness SM, Shibuya ML, Ueno AM, Vannais DB, Waldren CA. Mutant quantity and quality in mammalian cells (AL) exposed to cesium-137 γ radiation: effect of caffeine. Radiat Res 1995;142:247-55.
38. Thompson WG. Coffee: brew or bane? Am J Med Sci 1994;308:49-57.
39. Nehlig A, Debry G. Coffee and cancer: a review of human and animal data. World Rev Nutr Diet 1996;79:185-221.
40. Hsu TC, Johnston DA, Cherry LM, et al. Sensitivity to genotoxic effects of bleomycin in humans: possible relationship to environmental carcinogenesis. Int J Cancer 1989;43:403-9.
41. Cloos J, Nieuwenhuis EJ, Boomsma DI, et al. Inherited susceptibility to bleomycin-induced chromatid breaks in cultured peripheral blood lymphocytes. J Natl Cancer Inst 1999;91:1125-30.
42. Roberts SA, Spreadborough AR, Bulman B, Barber JB, Evans DG, Scott D. Heritability of cellular radiosensitivity: a marker of low-penetrance predisposition genes in breast cancer? Am J Hum Genet 1999; 65:784-94.
43. Helzlsouer KJ, Harris EL, Parshad R, Perry HR, Price FM, Sanford KK. DNA repair proficiency: potential susceptibility factor for breast cancer. J Natl Cancer Inst 1996;88:754-5.
44. Harms C, Salama SA, Sierra-Torres CH, Cajas-Salazar N, Au WW. Polymorphisms in DNA repair genes, chromosome aberrations, and lung cancer. Environ Mol Mutagen 2004;44:74-82.
45. Affatato AA, Wolfe KJ, Lopez MS, Hallberg C, Ammenheuser MM, Abdel-Rahman SZ. Effect of XPD/ERCC2 polymorphisms on chromosome aberration frequencies in smokers and on sensitivity to the mutagenic tobacco-specific nitrosamine NNK. Environ Mol Mutagen 2004;44:65-73.
46. Wang Y, Spitz MR, Zhu Y, Dong Q, Shete S, Wu X. From genotype to phenotype: correlating XRCC1 polymorphisms with mutagen sensitivity. DNA Repair (Amst) 2003;2:901-8.
47. Spitz MR, Fueger JJ, Halabi S, Schantz SP, Sample D, Hsu TC. Mutagen sensitivity in upper aerodigestive tract cancer: a case-control analysis. Cancer Epidemiol Biomarkers Prev 1993;2:329-33.
48. IARC, Mycotoxins: aflatoxins; studies of cancer in experimental animals. In: Anonymous, IARC Monographs on the evaluation of carcinogenic risks to humans. Lyon (France): IARC; 1993. p. 263-395.
49. Oyama T, Kawamoto T, Mizoue T, et al. Cytochrome P450 2E1 polymorphism as a risk factor for lung cancer: in relation to p53 gene mutation. Anticancer Res 1997;17:583-7.
50. Broaddus VC. Asbestos, the mesothelial cell and malignancy: a matter of life or death. Am J Respir Cell Mol Biol 1997;17:657-9.
51. Roy SK, Trivedi AH, Bakshi SR, et al. Bleomycin-induced chromosome damage in lymphocytes indicates inefficient DNA repair capacity in breast cancer families. J Exp Clin Cancer Res 2000;19:169-73.
52. Sanford KK, Price FM, Rhim JS, Stampfer MR, Parshad R. Role of DNA repair in malignant neoplastic transformation of human mammary epithelial cells in culture. Carcinogenesis 1992;13:1137-41.
53. Gowen LC, Avrutskaya AV, Latour AM, Koller BH, Leadon SA. BRCA1 required for transcription-coupled repair of oxidative DNA damage. Science 1998;281:1009-12.
54. Scully R, Chen J, Ochs RL, et al. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell 1997; 90:425-35.
55. Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev 1996;10:1054-72.
56. Brogger A, Norum R, Hansteen IL, et al. Comparison between five Nordic laboratories on scoring of human lymphocyte chromosome aberrations. Hereditas 1984;100:209-18.
57. Boren HG, Wright EC, Harris CC. Quantitative light microscopic autoradiography. In: Prescott D, editor. Methods in cell biology, vol. 8. New York: Academic Press; 1974. p. 277-88.